Envafolimab

恩沃利单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameEnvafolimab
Drug Alias NameEnvollizumabEmvollizumabEmvolizumabEnvolizumabEnvolimab +[9] 
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Single-domain antibody (Nanobody)Biologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionProgrammed death-ligand 1 blockersAntibody-dependent cell-mediated cytotoxicity (ADCC) effectsT lymphocytes stimulants
TargetsProgrammed death-ligand 1
Therapy Area/IndicationsGastroesophageal Junction NeoplasmsSolid tumoursMicrosatellite instability-high cancer +[20] 
Global Approved IndicationsMicrosatellite instability-high cancerMismatch Repair Deficient Cancer
Approved Indications in ChinaMicrosatellite instability-high cancerMismatch Repair Deficient Cancer
Original Approved Country/TerritoryMainland China
Original Approved Date2021/11/25
Country/TerritoryUnited StatesUnited KingdomMacau +[5] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesSuzhou Alphamab Co Ltd3d Medicines (Sichuan) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesAscletis Pharma IncAlphamab Oncology3d Medicines Inc +[13] 
Inactive CompaniesN/A
Active IndicationsSolid tumoursMicrosatellite instability-high cancerMismatch Repair Deficient Cancer +[18] 
Inactive IndicationsGastroesophageal Junction NeoplasmsStomach Neoplasms

Other Information

ATC CodeN/A
Related LinksDrugBank